Attributable mortality of candidemia at a German tertiary hospital from 1997 to 2001 before the introduction of echinocandins

The relevance of candidemia has increased over the last decades due to higher incidence rates in an ageing society. Studies on amphotericin B and fluconazole have shown high attributable mortality rates of 38% and 49% in the United States. Incidence rates and locational factors might have an impact on the mortality rates at the University Hospital of Cologne (UHC), Germany.

[1]  M. Pirs,et al.  Candidaemia in Central Slovenia: A 12‐year retrospective survey , 2021, Mycoses.

[2]  D. Marriott,et al.  Risk factors for candidaemia: A prospective multi‐centre case‐control study , 2020, Mycoses.

[3]  H. Seifert,et al.  Attributable mortality of candidemia after introduction of echinocandins , 2020, Mycoses.

[4]  M. Hendrickx,et al.  Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals , 2018, Mycoses.

[5]  P. Martín-Dávila,et al.  Emerging trends in candidemia: a higher incidence but a similar outcome. , 2012, The Journal of infection.

[6]  I. Gould,et al.  Epidemiology and management of candidaemia – a retrospective, multicentre study in five hospitals in the UK , 2011, Mycoses.

[7]  Elie Azoulay,et al.  Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study* , 2011, Critical care medicine.

[8]  H. Seifert,et al.  In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates , 2007, Antimicrobial Agents and Chemotherapy.

[9]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Pittet,et al.  Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Shane Gillespie,et al.  Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Sobel,et al.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  R. Gaynes,et al.  Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A. Tortorano,et al.  European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. , 2002, The Journal of hospital infection.

[15]  H. Richet,et al.  Candidemia in French hospitals: incidence rates and characteristics. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  L. Saiman,et al.  Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. McClish,et al.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  E. Anaissie,et al.  Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Snydman,et al.  Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. , 1995, Archives of internal medicine.

[21]  J. Serody,et al.  Intravascular Catheter Exchange and Duration of Candidemia , 1995 .

[22]  M. Levenstein,et al.  A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .

[23]  R F Woolson,et al.  Hospital-acquired candidemia. The attributable mortality and excess length of stay. , 1988, Archives of internal medicine.

[24]  A. Groll,et al.  Nosocomial Infections and Multidrug-resistant Organisms in Germany: Epidemiological Data From KISS (The Hospital Infection Surveillance System) , 2011 .

[25]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Rex,et al.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. , 1994, The New England journal of medicine.

[27]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.